PubMed Health⌕ Search

Biomedical subjects

M Jogee

Publications and source records attributed to M Jogee.

11 recordsLinked to original sources
PubMed1983

Decreased prostacyclin production by placental cells in culture from pregnancies complicated by fetal growth retardation.

Production of prostacyclin (PGI2) in vitro by human placental cells from pregnancies complicated by fetal growth retardation was significantly reduced compared with that in placental cells from normal pregnancies of either matched gestation or at term. This appeared to be due to a reduction of synthesis of PGI2 rather than to any alteration in the rate of its enzymic metabolism. Addition of oestradiol and progesterone increased PGI2 production by cells from pregnancies with fetal growth retardation in a similar manner to that by cells from first trimester pregnancies, implying that the placental cells are not irreversibly damaged by ischaemia. The decreased PGI2 production by cells of trophoblastic origin may be an aetiological factor in the thrombotic occlusion of the uteroplacental circulation which impairs fetal growth.

Cells, Cultured↗
PubMed1982

Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours.

Peripheral plasma levels of immunoreactive 6-oxo-PGF1 alpha, the stable hydrolysis product of prostacyclin, were significantly higher in female patients with tumours of the genital tract than in normal controls. In the groups with malignant tumours, these high levels declined after operation and/or radiotherapy if the tumour responded to treatment. In patients who did not respond to treatment or with tumour recurrence, levels of plasma 6-oxo-PGF1 alpha remained high or even rose further. Benign gynaecological tumours were also associated with significantly raised plasma 6-oxo-PGF1 alpha levels, and these fell to normal levels immediately on surgical removal of the tumour. Possible reasons for these alterations are described. Further investigations are warranted to see whether serial measurements of plasma 6-oxo-PGF1 alpha could be used as a prognostic index for the clinical status of patients with gynaecological tumours.

6-Ketoprostaglandin F1 alpha↗
PubMed1981

A comparison of the quantitative analysis of 6-oxo-PGF1 alpha in biological fluids by gas chromatography mass spectrometry and radioimmunoassay.

Two sensitive and selective quantitative methods for 6-oxo-PGF1 alpha, the stable hydrolysis product of prostacyclin are described and compared. Prostaglandins were extracted from biological fluids with organic solvents. Samples for gas chromatographic mass spectrometric analysis required additional thin-layer chromatographic separation prior to conversion to the O-methyloxime, methyl ester, tri-trimethylsilyl ether. Ion fragments at m/z 418 and 508 (protium) and m/z 422 and 512 (deuterium) were monitored to prepare 6-oxo-PGF1 alpha standard curves. The gas chromatographic mass spectrometric detection limit was 500 pg injected on column with a method coefficient of variation of 11.6% at this level. At 590 pg ml-1 the coefficient of variation for reproducibility of measurement was 1.77%. Antisera raised against a 6-oxo-PGF1 alpha-bovine serum albumin conjugate in sheep had a higher titre and greater selectivity than those raised in rabbits. Cross-reaction of sheep antisera with all prostaglandins and fatty acids tested was less than 0.5%. The radioimmunoassay limit of detection was 60 pg ml-1 (6 pg per tube) with a coefficient of variation of 10.4% (intra-assay) and 10.75% (inter-assay). The double blind comparison of gas chromatographic mass spectrometric and radioimmunoassay quantitation of the same samples gave a correlation coefficient of 0.97. Both methods offer sensitivity, selectivity and reproducibility. Gas chromatography mass spectrometry is necessary to validate the radioimmunoassay method which offers advantages of time, sample capacity and volume, expenditure and sensitivity.

6-Ketoprostaglandin F1 alpha↗
PubMed1980

Prostacyclin formation by the pregnant human myometrium.

Human myometrium taken between 15 and 42 weeks of pregnancy released a material in vitro which possessed anti-aggregatory activity. This material parallelled authentic prostacyclin in this action; it possessed a similar stability at alkaline pH and generation of activity was inhibited by indomethacin. Production of the prostacyclin-like material by the myometrium was similar at weeks 15 and 38 of pregnancy but a 4-fold increase in synthesis had occurred by 40 weeks. It is suggested this increase may be important for parturition.

Adenosine Diphosphate↗
PubMedDate not supplied

Prostacyclin production by human placental cells in short-term culture.

Human placentae of varying gestational ages have been cultured in vitro with little variation in cell type and pattern of growth found. Cell types found are similar morphologically and histochemically to those previously described. The biological specificity of the cells in culture was also confirmed by human placental lactogen production. Placental cells in culture appear to synthesize and release PGI2 which can be identified by gas chromatography-mass spectrometry. Production of PGI2 was routinely measured by radioimmunoassay (RIA) for 6-oxo-PGF1alpha and 13,14-dihydro-6,15-dioxo-PGF1alpha in culture supernatants. Good agreement was found between RIA and gas chromatography-mass spectrometry measurements. PGI2 production in culture was not affected by mode of delivery, and synthetic capability was found to increase with gestational age. Production of PGI2 by cells from preterm and term placentae was similar but significantly greater than that of first-trimester cells. As the proportion of PGI2 produced in culture supernatants as 13,14-dihydro-6,15-dioxo-PGF1alpha changed with time of incubation, it appears pertinent to measure this metabolite when assessing total PGI2 production. Synthesis of PGI2 wa inhibited by the cyclo-oxygenase inhibitors indomethacin and aspirin and PGI2 synthetase inhibitor 15 hydroperoxyarachidonic acid. However, in the culture system tranylcypromine, a putative specific inhibitor of PGI2 synthetase, produced weak inhibition only before becoming cytotoxic. The cell culture system appears to offer a reliable and reproducible means for measuring placental PGI2 production in vitro and in which to study factors controlling its production and metabolism.

Arachidonic Acids↗